Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ENDOMETRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ENDOMETRIN.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs ENDOMETRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Category D/X
Category C
Progestin + Estrogen
Progestin